Table 2. Clinical and Hematological Parameters of the CML Patients Examined at the Baseline and Later during the Follow Up after the Initiation of Imatinib Treatment, at 1.5 Months, 3 Months, 6 Months, and 12 Months.

parameters ⇒ (N = 36) (*in peripheral blood sample)		Hb gm %	TLC (103/μL)*	platelet count (103/μL)*	eosinophils (%)*	basophils (%)*	blasts (%)*	spleen size (cms below costal margin)
at baseline before therapy	mean ± SD	9.8 ± 1.88	210 ± 117	301 ± 91	3.4 ± 2	4.8 ± 3.9	2.9 ± 2.2	6.6 ± 3.1
	median (interquartile range)	9.35 (8.6–11.2)	207 (103–261)	290 (239–403)	3 (2–4)	4 (2–6)	2 (2–3)	6 (5–7)
after 1.5 months of imatinib therapy	mean ± SD	10.5 ± 1.74	30 ± 74	280 ± 90	3.7 ± 2.4	4 ± 3.6	2.5 ± 5	splenomegaly not found in 14 patients
	median (interquartile range)	10.7 (9.17–11.5)	16 (9–27)	272 (228–350)	3 (2–5)	3 (2–6)	2 (0–3)
after 3 months of imatinib therapy	mean ± SD	12.5 ± 1.69	21 ± 61	238 ± 114	2.6 ± 1.6	1.9 ± 3.3	0.9 ± 4.3	splenomegaly not found in 29 patients
	median (interquartile range)	12.7 (11.38–13.4)	11 (8–12)	205 (148–310)	2 (2–3)	1.5 (0–2)	0 (0–0)
after 6 months of imatinib therapy	mean ± SD	12.7 ± 1.61	15 ± 39	214 ± 80	2.8 ± 1.5	0.8 ± 1.3	0.7 ± 3	splenomegaly not found in 32 patients
	median (interquartile range)	12.85 (11.6–13.6)	8 (6–10)	202 (153–267)	2.5 (2–3)	0.5 (0–1)	0 (0–0)
after 12 months of imatinib therapy	mean ± SD	12.77 ± 1.55	13 ± 37	220 ± 117	2.3 ± 2	1 ± 2.8	0.7 ± 4	splenomegaly not found in 35 patients
	median (interquartile range)	13 (11.81–13.78)	6 (5–8)	201 (139–250)	2 (1–3)	0 (0–1)	0 (0–0)